Progen’s Experimental Drug Fails in Lung Cancer Study
Progen Pharmaceuticals Ltd., the Australian developer of oncology medicines, said its leading product candidate failed a study in patients with advanced lung cancer.
This entry was posted on Monday, September 24th, 2007 at 6:01 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.